Key result
VAP lipid testing refines cardiovascular risk assessment beyond traditional LDL-C measurement.
Answers are grounded in this paper and cite their sources.
In the past several decades, multiple clinical trials have demonstrated the effects of dyslipidemia beyond low density lipoprotein cholesterol (LDL-C) on predicting risk for atherosclerosis and cardiovascular disease. In recent years there has been a proliferation of lipoprotein markers that, when used with LDL-C, help healthcare providers assess risk of patients on the basis of the cardiovascular risk spectrum. In this review, we will discuss some of the important reasons why traditional lipoprotein testing has failed in high risk populations and how unique lipoprotein testing by the Vertical Auto Profile (VAP) Lipid panel is to provide significant clarity to a difficult disease for its management and treatment. We will also discuss some of the new trials that address newer markers of risk that have robust outcomes even after adjusting for traditional cardiovascular disease risk factors.
No takes yet. Share an insight, caveat, or question.
French et al. (2017) conducted a review in Coronary artery disease (CAD) and dyslipidemia. Vertical Auto Profile (VAP) lipid panel vs. Traditional lipoprotein testing (LDL-C) was evaluated. Vertical Auto Profile (VAP) lipid panel testing is reviewed for its role in clarifying cardiovascular risk beyond traditional LDL-C testing; no quantitative data are reported in the abstract.
Synapse has enriched 10 related papers. Consider them for comparative context: